Find out what the numbers really say — before the market does
Analyze now
News Sentiment
Are today's headlines a buy signal or a red flag?
Analyze now
Buy / Hold / Sell
Should you Buy, Hold, or Sell? Get the AI verdict now.
Analyze now
Risk Assessment
Uncover hidden risks before they hit your portfolio.
Analyze now
Fair Value
Is this stock cheap, fairly priced, or overvalued?
Analyze now
Latest AI Analyses of Statera Biopharma, Inc.
No Price
01.05.2026 17:42
Current Prices from Statera Biopharma, Inc.
Exchange
Ticker
Currency
Last Trade
Price
Daily Change
UTC
STAB
USD
01.05.2026 17:42
0,0001 USD
0,00 USD
NASDAQ
STAB
USD
01.05.2026 17:42
0,0001 USD
0,00 USD
Share Float & Liquidity
Free Float67,36 %
Shares Float48,11 M
Shares Outstanding71,42 M
Company Profile for Statera Biopharma, Inc. Share
Statera BioPharma, Inc., a clinical-stage biopharmaceutical company, develops novel immunotherapies targeting autoimmune, neutropenia/anemia, emerging viruses, and cancers based on a proprietary platform designed to rebalance the body's immune system and restore homeostasis. The company is developing therapies designed to directly elicit within patients a response of antigen-specific killer T-cells and antibodies, thereby activating essential immune defenses against autoimmune, inflammatory, infectious diseases, and cancers. It has clinical programs for Crohn's disease (STAT-201), hematology (Entolimod), pancreatic cancer (STAT-401), and COVID-19 (STAT-205), as well as expanding into fibromyalgia and multiple sclerosis. The company was formerly known as Cytocom, Inc. and changed its name to Statera Biopharma, Inc. in September 2021. The company is based in Fort Collins, Colorado.
